Product
Reverse transcriptase polymerase chain reaction
1 clinical trial
2 indications
Indication
Ovarian CancerIndication
Primary Peritoneal Cavity CancerClinical trial
Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerStatus: Completed, Estimated PCD: 2012-08-01